Neurology

FDA approved zilganersen (ZANVASTRO), the first disease-modifying treatment for Alexander disease, based on pivotal trial data.

Ninety-six percent of the study population also had confirmed chronic traumatic encephalopathy on autopsy.

At an AJMC roundtable, Atlanta clinicians detailed blood-based biomarker gaps, uncompensated care, and capacity strains slowing Alzheimer diagnosis.

Researchers found no evidence that cooling beyond 6 hours at 33°C improved neurological outcomes in comatose survivors of out-of-hospital cardiac arrest.

MASLD/MASH was associated with higher mild cognitive impairment risk and lower dementia odds, but competing risks may explain the latter finding.

The meta-analysis of 17 studies found that frailty was strongly associated with cognitive impairment in CKD, highlighting the need for further research to determine a causal relationship.

Smartphone remote monitoring captures between-visit symptom changes in myasthenia gravis, spotting week-to-week swings and enabling earlier symptom management than clinic visits.

The FDA approved LEQEMBI IQLIK for once-weekly at-home subcutaneous initiation in early Alzheimer's disease based on IV and extension study data.

Veterans with Alzheimer disease (AD), identified using clinical notes, have higher health care utilization than veterans without AD.

The approval marks the first treatment for the rare disease marked by rapid and sustained weight gain caused by hypothalamic injury or dysfunction.

Wildfire smoke from the Canadian wildfires in 2023 was linked to a higher incidence of severe strokes and increased hemorrhagic risk, according to new study findings.

There is a shift happening in mental health care, with real-world data and holistic evaluations improving patient outcomes and reducing disparities.

Developers say more accurate automated multiple sclerosis lesion segmentation can improve research and patient care.

Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new disease-modifying therapies.

In 2025, each issue of Population Health, Equity & Outcomes has featured a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with B. Joy Snider, MD, PhD, professor of neurology at Washington University in St Louis.

Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for treating Alzheimer disease and multiple sclerosis.

Experts at an Institute for Value-Based Medicine event held October 14, 2025, in Aurora, Colorado, explored advances in neurology care, cross-specialty collaboration, and strategies to improve access and therapy.

Ken Cohen, MD, FACP, discusses how clinicians can support patients after a cognitive screening to identify meaningful next steps.

Medicare expenditures for patients with amyotrophic lateral sclerosis are more than 3 times those of the average Medicare beneficiary, and drug therapies are an important cost driver.

Lesion-based disconnectome mapping suggests that the pattern, not the quantity, of brain damage determines cognitive outcomes in patients with MS.

Navigating treatment for multiple sclerosis and comorbid inflammatory diseases presents unique challenges, requiring careful, interdisciplinary strategies for optimal patient care.

Givinostat shows promise in delaying Duchenne muscular dystrophy (DMD) progression, enhancing mobility, and maintaining safety in long-term treatment.

New insights reveal how early intervention in radiologically isolated syndrome can delay multiple sclerosis (MS) onset and improve patient outcomes.

New findings demonstrate an association between increased cumulative depression genetic burden and multiple sclerosis (MS) disease activity.

DYNE-251 received FDA breakthrough therapy designation, showcasing its potential for patients with Duchenne muscular dystrophy (DMD).